Serum levels of club (Clara) cell secretory protein predict cancer mortality in adults

Background— Club (formerly Clara) cell secretory protein (CC16) is produced mainly by bronchiolar club cells and has been shown to have protective effects against airway inflammation and oxidative stress from cigarette smoking and related carcinogens. The goal of this study was to determine whether serum CC16 levels predict all-cause and cancer-specific mortality in adults. Methods— We used data from the population-based TESAOD study, a prospective cohort study of respiratory health initiated in Tucson, AZ in 1972. At baseline, participants completed standardized respiratory questionnaires and lung function tests. Serum CC16 was measured in cryopreserved serum samples. A review of vital status of participants as of January 1 st , 2011 was completed through contact with next of kin, collection of death certificates, and linkage with the National Death Index. Findings— A total of 1086 participants who were 21 to 70 years old at enrollment were included. Of these, 653 (60%) died by 2011 and cause of death was ascertained for 649 (99%). In Cox proportional hazards models adjusted for sex, age, education, body mass index categories, smoking and pack-years, and baseline levels of lung function, serum CC16 levels at the baseline survey were inversely associated with mortality risk over the study follow-up. Mortality risk increased by 16% for each standard deviation (SD) decrease in CC16 (Hazard Ratio (HR), 95% CI: 1.16, 1.06 – 1.26; p = 0.0007). When data on cause-specific mortality were analyzed, each SD decrease in serum CC16 was associated with >40% increased risk of dying of cancer (adjusted

[1]  S. Guerra,et al.  Serum levels of Clara cell secretory protein, asthma, and lung function in the adult general population. , 2013, The Journal of allergy and clinical immunology.

[2]  H. Morgenstern,et al.  Systematic Reviews and Meta-and Pooled Analyses Previous Lung Diseases and Lung Cancer Risk : A Pooled Analysis From the International Lung Cancer Consortium , 2012 .

[3]  L. Edwards,et al.  Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[4]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[5]  D. Yeager,et al.  The Validity of Self-Reported Nicotine Product Use in the 2001–2008 National Health and Nutrition Examination Survey , 2010, Medical care.

[6]  E. Riboli,et al.  Occupational exposures contribute to educational inequalities in lung cancer incidence among men: Evidence from the EPIC prospective cohort study , 2010, International journal of cancer.

[7]  Yi-Ching Lee,et al.  Lack of an Endogenous Anti-inflammatory Protein in Mice Enhances Colonization of B16F10 Melanoma Cells in the Lungs* , 2010, The Journal of Biological Chemistry.

[8]  K. Straif,et al.  A review of human carcinogens--Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. , 2009, The Lancet. Oncology.

[9]  L. Edwards,et al.  Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort , 2008, Thorax.

[10]  A. Mukherjee,et al.  Uteroglobin: a steroid-inducible immunomodulatory protein that founded the Secretoglobin superfamily. , 2007, Endocrine reviews.

[11]  Robert West,et al.  Can We Trust National Smoking Prevalence Figures? Discrepancies Between Biochemically Assessed and Self-Reported Smoking Rates in Three Countries , 2007, Cancer Epidemiology Biomarkers & Prevention.

[12]  S. Holgate,et al.  A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects , 2007, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[13]  S. Lam,et al.  The Association between the Anti-inflammatory Protein CC10 and Smoking Status among Participants in a Chemoprevention Trial , 2006, Cancer Epidemiology Biomarkers & Prevention.

[14]  A. Mukherjee,et al.  Increased Susceptibility of Mice Lacking Clara Cell 10-kDa Protein to Lung Tumorigenesis by 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, a Potent Carcinogen in Cigarette Smoke* , 2004, Journal of Biological Chemistry.

[15]  L. Lehman-Mckeeman,et al.  Immunohistochemical analysis of Clara cell secretory protein expression in a transgenic model of mouse lung carcinogenesis. , 2003, Toxicology.

[16]  A. Malkinson,et al.  The Role of CC10 in Pulmonary Carcinogenesis: From a Marker to Tumor Suppression , 2000, Annals of the New York Academy of Sciences.

[17]  A. Bernard,et al.  Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  C. Yuan,et al.  Loss of transformed phenotype in cancer cells by overexpression of the uteroglobin gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C Hermans,et al.  Lung epithelium-specific proteins: characteristics and potential applications as markers. , 1999, American journal of respiratory and critical care medicine.

[20]  E. Szabo,et al.  Overexpression of CC10 modifies neoplastic potential in lung cancer cells. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[21]  T. Yamaguchi,et al.  Serum and BAL Clara cell 10 kDa protein (CC10) levels and CC10-positive bronchiolar cells are decreased in smokers. , 1997, The European respiratory journal.

[22]  H. Roels,et al.  Serum Clara cell protein: an indicator of bronchial cell dysfunction caused by tobacco smoking. , 1994, Environmental research.

[23]  L. Fisher,et al.  A test of the National Death Index using the Coronary Artery Surgery Study (CASS). , 1985, Controlled clinical trials.

[24]  M. Lebowitz,et al.  Changes in the normal maximal expiratory flow-volume curve with growth and aging. , 1983, The American review of respiratory disease.

[25]  M. Lebowitz,et al.  The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. , 1976, The American review of respiratory disease.

[26]  M. Lebowitz,et al.  Tucson epidemiologic study of obstructive lung diseases. I: Methodology and prevalence of disease. , 1975, American journal of epidemiology.

[27]  M. Doody,et al.  Comparability of national death index plus and standard procedures for determining causes of death in epidemiologic studies. , 2001, Annals of epidemiology.